Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
X-linked intellectual disability-retinitis pigmentosa syndrome is characterized by moderate intellectual deficit and severe, early-onset retinitis pigmentosa. It has been described in five males spanning three generations of one family. Some patients also had microcephaly. It is transmitted as an X-linked recessive trait.
Features include always present findings: Rod-cone dystrophy, Global developmental delay, and Visual impairment; and very common findings: Intellectual disability and Iris hypopigmentation. 24 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 9 | Pigmentary retinopathy, Cataract, Blindness |
Phenotype severity distribution: 3 always present features, 2 very common features, 2 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for X-linked intellectual disability-retinitis pigmentosa syndrome.
7 publications have been identified in PubMed for X-linked intellectual disability-retinitis pigmentosa syndrome. Research spans Review / Meta-Analysis (57%), Case Report / Case Series (14%), and Clinical Trial Publication (14%).
Wang Y (2025). [PMID: 40813981](https://pubmed.ncbi.nlm.nih.gov/40813981/). *BMC Ophthalmol*. [Case Report / Case Series]
Janáky M (2025). [PMID: 39846623](https://pubmed.ncbi.nlm.nih.gov/39846623/). *Vision (Basel)*. [Review / Meta-Analysis]
Lopez-de la Rosa A (2024). [PMID: 38872169](https://pubmed.ncbi.nlm.nih.gov/38872169/). *Orphanet J Rare Dis*. [Epidemiology / Natural History]
Ribeiro JAS (2024). [PMID: 38947102](https://pubmed.ncbi.nlm.nih.gov/38947102/). *Yale J Biol Med*. [Review / Meta-Analysis]
Campos FG (2024). [PMID: 38958348](https://pubmed.ncbi.nlm.nih.gov/38958348/). *Arq Bras Cir Dig*. [Review / Meta-Analysis]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 12:43 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about X-linked intellectual disability-retinitis pigmentosa syndrome
Brain and nerves
4 |
Bilateral tonic-clonic seizure, Intellectual disability, Global developmental delay |
Head and neck | 2 | Progeroid facial appearance, Microcephaly |
Growth and development | 1 | Short stature |
Lungs and breathing | 1 | Asthma |
Muscles | 1 | Damage to the optic nerve (optic atrophy) |
Age of onset: infancy.
Dunleavy C (2024). [PMID: 38906488](https://pubmed.ncbi.nlm.nih.gov/38906488/). *Brain Behav Immun*. [Clinical Trial Publication]
Jung EH (2024). [PMID: 39257251](https://pubmed.ncbi.nlm.nih.gov/39257251/). *Ophthalmic Genet*. [Review / Meta-Analysis]
AI-curated news mentioning X-linked intellectual disability-retinitis pigmentosa syndrome
Updated Jul 31, 2026
A study identifies a rare dual Mendelian molecular diagnosis involving PAX6-associated aniridia and RPGR-related X-linked retinitis pigmentosa. This research enhances understanding of genetic factors in these conditions.
A new cost of illness model estimates the annual societal costs of X-linked retinitis pigmentosa (XLRP) in the UK, providing valuable insights for healthcare planning and resource allocation. This research highlights the economic burden of XLRP, which can inform policy decisions and funding priorities.